Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024 16:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company...
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
June 12, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 28, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating...
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
May 14, 2024 07:30 ET
|
Absci Corporation
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) --...
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
April 16, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business...
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 28, 2024 16:05 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be...
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024 07:30 ET
|
Absci Corporation
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened...
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 01, 2024 16:01 ET
|
Absci Corporation
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten...
Absci Announces Pricing of Public Offering of Common Stock
February 27, 2024 22:20 ET
|
Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten...
Absci Announces Proposed Public Offering of Common Stock
February 27, 2024 16:01 ET
|
Absci Corporation
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an...